Monika Vnuk and Matt Lane join Blackstone Life Sciences as Managing Directors
13 Ottobre 2021 - 2:00PM
Business Wire
Blackstone Life Sciences (“BXLS”), Blackstone’s
life sciences business, announced today that Dr. Monika Vnuk and
Matt Lane have joined BXLS as Managing Directors in the firm’s
Cambridge office. Dr. Vnuk joins from Pfizer, where she served as
Vice President of Worldwide Business Development, having recently
led Pfizer’s partnership with BioNTech for their COVID-19 vaccine.
Mr. Lane joins with more than 20 years of experience in advising
life sciences companies, including more than 15 years at Cowen
Group, a leading life sciences focused investment bank.
Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences
said: “We are excited to welcome Monika and Matt to the team. Their
collective expertise in complex deal structuring, and their
networks in the biopharmaceutical sector will help us expand our
investment activities as we seek to advance important medicines to
patients.”
Before joining Blackstone Life Sciences, Dr. Vnuk spent nearly
15 years in leadership roles at Pfizer, including most recently as
Vice President of Worldwide Business Development. In that role she
led the negotiation of the successful partnership with BioNTech
directed at the global co-development and distribution of COVID-19
vaccines. Before joining Pfizer, Dr. Vnuk worked in investment
banking at Bank of America and at Oxford Bioscience Partners, a
life sciences venture capital firm. Dr. Vnuk holds an MD degree
from the Boston University School of Medicine and a B.A. from
Boston University.
Prior to joining Blackstone Life Sciences, Mr. Lane was a
Managing Director at Gilmartin Group LLC, a strategic advisory
firm. Before joining Gilmartin, Mr. Lane spent more than 15 years
with Cowen Group as a Managing Director where he focused on
supporting life sciences companies at all stages of their
development. Before working in finance, Mr. Lane served as Press
Secretary to US Senator Judd Gregg. He received a B.A. from Amherst
College.
In July 2020, BXLS raised the largest private life sciences fund
to date and currently has more than $7 billion in assets under
management.
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private
investment platform with capabilities to invest across the life
cycle of companies and products within the key life science
sectors. By combining scale investments and hands-on operational
leadership, Blackstone Life Sciences helps bring to market
promising new medicines and medical technologies that improve
patients’ lives. More information is provided at
https://www.blackstone.com/our-businesses/life-sciences/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211013005621/en/
Paula Chirhart +1-347-463-5453 paula.chirhart@blackstone.com
Grafico Azioni Blackstone (NYSE:BX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Blackstone (NYSE:BX)
Storico
Da Apr 2023 a Apr 2024